GS 4528
Alternative Names: GS-4528Latest Information Update: 16 Jun 2023
At a glance
- Originator Gilead Sciences
- Class Antineoplastics; Interleukins
- Mechanism of Action Interleukin-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 May 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in Canada (IV) (NCT05840224) (EudraCT2022-502070-16-00)
- 11 May 2023 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease) in Canada (IV) (NCT05840224) (EudraCT2022-502070-16-00)
- 09 May 2023 Gilead Sciences plans a phase I trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease) by May 2023 (IV) (NCT05840224 ) (EudraCT2022-502070-16-00)